Synthetic Cleavage-Resistant TREM2: A Novel Approach to Restoring Macrophage Function in Inflammatory Disease

Study Background and Research Question

Efficient clearance of apoptotic cells—efferocytosis—is critical for maintaining tissue homeostasis and preventing chronic inflammation. Macrophages, through the triggering receptor expressed on myeloid cells 2 (TREM2), play a central role in sensing and engulfing apoptotic debris. However, under inflammatory conditions, the protease ADAM17 is upregulated, leading to cleavage of TREM2 and disruption of this pathway. This proteolytic loss impairs macrophage phagocytosis, resulting in the pathological accumulation of cell corpses and unresolved inflammation, as observed in diseases such as atherosclerosis and metabolic-dysfunction-associated steatohepatitis (MASH). The central research question addressed by Dong et al. is whether engineering a form of TREM2 that resists proteolytic cleavage could restore macrophage efferocytosis and resolve inflammation (reference study).

Key Innovation from the Reference Study

The primary innovation presented by Dong et al. is the design and implementation of a synthetic, cleavage-resistant TREM2 receptor (CRT). This engineered receptor incorporates the ligand-binding domain of TREM2, its intracellular signaling adaptor DAP12, and a custom stalk and transmembrane region that confers resistance to ADAM17-mediated cleavage. By preserving TREM2 integrity in the presence of elevated sheddase activity, CRT maintains and amplifies critical intracellular signaling necessary for efferocytosis. This design addresses a fundamental bottleneck in targeting TREM2 for therapeutic intervention in inflammatory diseases.

Methods and Experimental Design Insights

The study employs a multi-tiered experimental strategy:

• Receptor Engineering: Generation of CRT constructs with defined modifications in the stalk region to prevent ADAM17 cleavage, while retaining functional ligand-binding and signaling domains.
• RNA Polymerase T7 Transcription and mRNA Synthesis: CRT mRNA was synthesized via in vitro transcription—a process highly relevant to current mRNA therapeutic workflows and closely related to protocols for fluorescent RNA probe synthesis and labeling.
• Lipid Nanoparticle (LNP) Formulation: The team designed phosphatidylserine-functionalized LNPs to encapsulate CRT mRNA, exploiting the natural targeting of aminophospholipids to macrophages to achieve selective delivery in vivo.
• In Situ Macrophage Engineering: Systemic administration of CRT-mRNA-LNPs in mouse models enabled in situ reprogramming of tissue macrophages to express the synthetic receptor, bypassing the need for ex vivo cell manipulation.
• Disease Models: The efficacy of CRT-Ms (CRT-expressing macrophages) was evaluated in two independent models: atherosclerosis and MASH, both characterized by inflammatory apoptotic cell accumulation.

The application of T7 RNA polymerase-driven transcription for mRNA construct synthesis parallels advanced probe preparation methods in molecular biology, including those used for in situ hybridization probe preparation and Northern blot hybridization probe design.

Core Findings and Why They Matter

Diversified experimental readouts revealed that CRT expression in macrophages:

• Resisted ADAM17-mediated proteolytic cleavage, maintaining cell-surface TREM2 levels even during inflammation.
• Amplified downstream DAP12/ITAM signaling, as evidenced by increased phosphorylation events and effector gene expression.
• Restored efferocytosis capacity in vitro and in vivo, leading to more efficient apoptotic cell clearance.
• Reduced inflammatory marker expression and tissue damage in both MASH and atherosclerosis mouse models (Dong et al.).

These results substantiate the hypothesis that enhancing TREM2 signaling by protecting against proteolytic loss can directly improve macrophage-mediated tissue repair and limit the progression of chronic inflammatory diseases. The use of LNPs for mRNA delivery is consistent with the broader trend in both gene therapy and probe-based research, where targeted, efficient, and cell-specific delivery is paramount.

Protocol Parameters

• CRT mRNA Synthesis: In vitro transcription with T7 RNA polymerase; template design incorporates the modified TREM2-DAP12 fusion with a cleavage-resistant stalk.
• LNP Formulation: Phosphatidylserine-functionalized lipids for macrophage targeting; encapsulation of synthesized CRT mRNA.
• In Situ Delivery: Systemic or localized administration of LNP-mRNA complexes to mouse models of inflammation; dosing optimized based on tissue uptake and desired macrophage reprogramming.
• Functional Readouts: Measurement of efferocytosis by flow cytometry and histology; quantification of inflammatory cytokines and tissue pathology.

Comparison with Existing Internal Articles

While Dong et al. focus on restoring signaling capacity in macrophages using synthetic mRNA constructs, numerous internal review articles have addressed the technical challenges and advances in in vitro RNA synthesis and probe labeling. For example, the article "Fluorescent RNA Probe Synthesis: Mechanistic Advances and Translational Opportunities" discusses the mechanistic parallels between mRNA therapeutic preparation and the creation of high-sensitivity fluorescent probes. Both workflows rely on precise control of T7 RNA polymerase-driven transcription and, in some protocols, the incorporation of modified nucleotides for downstream detection or functionalization.

Similarly, "HyperScribe T7 High Yield Cy5 RNA Labeling Kit: Fluorescence in Gene Expression Analysis" provides practical guidance on optimizing Cy5-UTP incorporation during RNA labeling, which is directly relevant for researchers designing probes or RNA constructs for in situ hybridization or functional delivery. Although the focus in Dong et al. is on therapeutic mRNA, the technical overlap with these workflows—especially regarding RNA purity, yield, and sequence fidelity—remains substantial.

Limitations and Transferability

Despite the promise of CRT-mRNA-LNP technology, several limitations warrant consideration. The primary data are derived from murine models, and while the approach demonstrates robust efficacy in this context, the translatability to human systems—particularly regarding immunogenicity, mRNA stability, and LNP biodistribution—requires further investigation. Additionally, long-term effects of persistent CRT expression in tissue macrophages, such as potential off-target immune modulation, have not been fully addressed. Mechanistically, the degree to which CRT can compensate for all facets of native TREM2 function remains to be determined.

It is also important to note that while in vitro transcription and mRNA delivery protocols are well established, the optimal design for each application, including probe synthesis versus therapeutic mRNA, may differ in the choice of modifications (e.g., nucleotide analogs, cap structures) and purification strategies. Thus, while lessons from this study are broadly applicable, direct transfer of protocol parameters should be undertaken with application-specific validation.

Why this cross-domain matters, maturity, and limitations

The intersection of therapeutic mRNA delivery and advanced RNA probe synthesis underlines the convergence of translational research and molecular diagnostics. Methods refined for efficient, high-yield, and site-specific RNA labeling—such as those highlighted in internal reviews—directly support the scalability and reproducibility of mRNA-based interventions. Nevertheless, the maturity of these platforms varies: mRNA-LNP therapeutics are in clinical use for vaccines but remain investigational for cell reprogramming, while fluorescent RNA labeling is already routine in gene expression and hybridization assays. Researchers should remain cognizant of the current regulatory, technical, and biological constraints when extending findings across domains.

Research Support Resources

For laboratories interested in adapting similar workflows—whether for in situ hybridization probe preparation, Northern blot hybridization probe development, or optimization of in vitro transcription RNA labeling—the HyperScribe™ T7 High Yield Cy5 RNA Labeling Kit (SKU K1062) provides a streamlined solution for efficient, customizable fluorescent RNA probe synthesis. The kit allows precise adjustment of Cy5-UTP incorporation, supporting sensitive detection needs. As underscored by current mechanistic studies and internal reviews, robust probe production and high-fidelity RNA synthesis are foundational for both advanced molecular analysis and translational mRNA research. Researchers can consult the internal article for additional methodological guidance and best practices when bridging probe synthesis with functional nucleic acid delivery workflows.